Valneva SE (WBO:VLA) LT-Debt-to-Total-Asset : 0.35 (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Valneva SE LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Valneva SE's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.35.

Valneva SE's long-term debt to total assets ratio increased from Sep. 2023 (0.26) to Sep. 2024 (0.35). It may suggest that Valneva SE is progressively becoming more dependent on debt to grow their business.

Valneva SE LT-Debt-to-Total-Asset Historical Data

The historical data trend for Valneva SE's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Valneva SE LT-Debt-to-Total-Asset Chart

Valneva SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.31

0.21

0.13

0.19

0.35

Valneva SE Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.26	0.35	0.37	0.40	0.35

Valneva SE LT-Debt-to-Total-Asset Calculation

Valneva SE's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	161.858	/	460.062
	=	0.35

Valneva SE's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	179.141	/	516.614
	=	0.35

Valneva SE (WBO:VLA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Valneva SE LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Valneva SE's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Valneva SE Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valneva SE (WBO:VLA) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

VALN:USA INRLF:USA VLAp:UK 0OB3:UK VLA:France AYJ:Germany AYJ0:Germany AYJ0:Germany AYJ:Germany AYJ:Germany AYJ:Germany AYJ:Bulgaria

Address

6 Rue Alain Bombard, Saint-Herblain, FRA, 44800

Website

https://www.valneva.com

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.

Valneva SE Headlines

No Headlines